Page 36 - RECCMI_Diciembre_20
P. 36

Cruz M, Graña-Cruz DC, Pérez L, Gaudiano J. Rituximab en lupus sistémico ampolloso


          2.  Crow MK. Etiology and Pathogenesis of Systemic Lupus Erythematosus,   tions and outcomes of bullous systemic lupus erythematosus: 10 New ca-
            Tenth Edit, Elsevier Inc, 2017. doi:10.1016/B978-0-323-31696-5.00079-6.  ses and a literature review of 118 cases. Semin Arthritis Rheum. 2018; 48(1):
          3.  Sánchez-Navarro LM, Poletti ED, López-Domínguez NV, López SS, Sánchez-  83-89. doi: 10.1016/j.semarthrit.2017.11.003.
            Delgado MA. Lupus eritematoso sistémico ampolloso: reporte de un caso   10. Fruchter R, Kurtzman DJB, Patel M, Merola J, Franks AG Jr, Vleugels RA, et
            y revisión de la literatura. DermatologíaCMQ. 2012; 10(3): 182-187. (Ultimo   al. Characteristics and Alternative  Treatment Outcomes of Antimalarial-
            acceso Agosto 2020) Accesible en:  https://www.medigraphic.com/pdfs/  Refractory Cutaneous Lupus Erythematosus. JAMA Dermatol. 2017; 153(9):
            cosmetica/dcm-2012/dcm123e.pdf                      937-939. doi: 10.1001/jamadermatol.2017.1160.
          4.  Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Derma-  11. Penha MÁ, Libório RDS, Miot HA. Rituximab in the treatment of
            tol Clin. 2011; 29(4): 649-53. doi: 10.1016/j.det.2011.06.002.  extensive and refractory subacute cutaneous lupus erythemato-
          5.  Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of   sus. An Bras Dermatol. 2018; 93(3): 467-469. doi: 10.1590/abd1806-
            the SLEDAI. A disease activity index for lupus patients. The Committee on   4841.20187561.
            Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6): 630-40. doi: 10.1002/  12. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment
            art.1780350606.                                     of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011; 17(3):
          6.  Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best   142-4. doi: 10.1097/RHU.0b013e318214f30c.
            Pract Res Clin Rheumatol. 2013; 27(3): 391-404. doi: 10.1016/j.berh.2013.07.008.  13. Akpabio AA, Otike-Odibi BI. Severe bullous systemic lupus erythemato-
          7.  Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on   sus successfully treated with low dose rituximab: a case report from sub-
            pathogenesis and associations with systemic lupus. Curr Opin Rheumatol.   Saharan Africa. Reumatismo. 2020  Jul  23;72(2):115-119.  doi:  10.4081/
            2016; 28(5): 453-459. doi:10.1097/BOR.0000000000000308.  reumatismo.2020.1274.
          8.  Vico-Alonso C, Calleja-Algarra A, Andrés-Lencina JJ, Aragón-Miguel R, Pi-  14. Cieza-Díaz DE, Avilés-Izquierdo JA, Ceballos-Rodríguez C, Suárez-Fernández
            nilla-Martin B, Sánchez-Velázquez A, et al. Bullous eruption in a 1-year-old   R. Lupus eritematoso cutáneo subagudo refractario tratado con rituxi-
            female in the Philippines: A diagnostic challenge. (Poster in American Aca-  mab [Refractory subacute cutaneous lupus erythematosus treated with
            demy of Dermatology 2019 Annual Meeting). J Am Acad Dermatol. 2017;   rituximab]. Actas Dermosifiliogr. 2012 Jul-Aug;103(6):555-7. doi: 10.1016/j.
            81(4) suppl.1: AB177. doi: 10.1016/j.jaad.2019.06.660.  ad.2011.10.013.
          9.  de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-  15. Lowe CD, Brahe CA, Green B, Lam TK, Meyerle JH. Bullous systemic lupus
            Mignot S, Mathian A, et al. Clinical, histological, immunological presenta-  erythematosus successfully treated with rituximab. Cutis. 2019; 103(6): E5-E7.




















































                                                          136 Rev Esp Casos Clin Med Intern (RECCMI). 2020 (Dic); 5(3): 133-136
   31   32   33   34   35   36   37   38